The effect of bisphosphonate therapy on reducing the risk of cardiovascular complications associated with chronic heart failure, type 2 diabetes and osteoporosis in postmenopausal women
- Authors: Teplyakov AT1, Berezikova EN2, Shilov SN2, Popova AA2, Samsonova EN2, Yakovleva IV2, Molokov AV2, Grakova EV1, Kopeva KV1
-
Affiliations:
- Cardiology Research Institute, Tomsk National Research Medical Center
- Novosibirsk State Medical University
- Issue: Vol 91, No 10 (2019)
- Pages: 63-69
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33699
- DOI: https://doi.org/10.26442/00403660.2019.10.000162
- ID: 33699
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A T Teplyakov
Cardiology Research Institute, Tomsk National Research Medical Centerд.м.н., проф., гл.н.с. НИИ кардиологии ТНИМЦ; ORCID: 0000-0003-0721-0038 Tomsk, Russia
E N Berezikova
Novosibirsk State Medical Universityд.м.н., доц. каф. поликлинической терапии и общей врачебной практики ФГБОУ ВО «НГМУ»; ORCID: 0000-0002-9630-0213 Novosibirsk, Russia
S N Shilov
Novosibirsk State Medical University
Email: newsib54@gmail.com
д.м.н., доц. каф. патологической физиологии и клинической патофизиологии ФГБОУ ВО «НГМУ»; ORCID: 0000-0002-7777-6419 Novosibirsk, Russia
A A Popova
Novosibirsk State Medical Universityд.м.н., зав. каф. поликлинической терапии и общей врачебной практики ФГБОУ ВО «НГМУ»; ORCID: 0000-0003-2645-162Х Novosibirsk, Russia
E N Samsonova
Novosibirsk State Medical Universityд.м.н., проф., зав. каф. патологической физиологии и клинической патофизиологии ФГБОУ ВО «НГМУ»; ORCID: 0000-0001-6986-7305 Novosibirsk, Russia
I V Yakovleva
Novosibirsk State Medical Universityассистент каф. поликлинической терапии и общей врачебной практики ФГБОУ ВО «НГМУ»; ORCID: 0000-0003-4712-2315 Novosibirsk, Russia
A V Molokov
Novosibirsk State Medical Universityассистент каф. поликлинической терапии и общей врачебной практики ФГБОУ ВО «НГМУ»; ORCID: 0000-0001-8718-2801 Novosibirsk, Russia
E V Grakova
Cardiology Research Institute, Tomsk National Research Medical Centerд.м.н., в.н.с. отд-ния патологии миокарда НИИ кардиологии ТНИМЦ; ORCID: 0000-0003-4019-3735 Tomsk, Russia
K V Kopeva
Cardiology Research Institute, Tomsk National Research Medical Centerлаборант-исследователь отд-ния патологии миокарда НИИ кардиологии ТНИМЦ; ORCID: 0000-0002-2285-6438 Tomsk, Russia
References
- Von der Recke P, Hansen M.A, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106(3):273-8. doi: 10.1016/s0002-9343(99)00028-5
- Kado D.M, Browner W.S, Blackwell T, Gore R, Cummings S.R. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000;15(10):1974-80. doi: 10.1359/jbmr.2000.15.10.1974
- Mussolino M.E, Gillum R.F, Madans J.H. Bone mineral density and stroke risk. Stroke. 2001;32(12):2956-7. doi: 10.1161/str.32.12.2956
- Laroche M, Pécourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, Sutter B, Degboe Y. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84(4):427-32. doi: 10.1016/j.jbspin.2016.09.022
- Lee S.H, Kim T.S, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008;41(7):495-510. doi: 10.5483/bmbrep.2008.41.7.495
- Sprini D, Rini G.B, Stefano L.D, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117-9. doi: 10.11138/ccmbm/2014.11.2.117
- Шилов С.Н., Тепляков А.Т., Яковлева И.В., Попова А.А., Березикова Е.Н., Гракова Е.В., Молоков А.В., Неупокоева М.Н., Кобец В.В., Копьева К.В., Гармаева О.В. Клиническая и патогенетическая взаимосвязь хронической сердечной недостаточности, сахарного диабета 2 типа и остеопороза. Комплексные проблемы сердечно - сосудистых заболеваний. 2018;7(1):6-13. doi: 10.17802/2306-1278-2018-7-1-6-13
- Rennenberg R.J, Kessels A.G, Schurgers L.J, van Engelshoven J, de Leeuw P.W, Kroon A.A. Vascular calcifications as a marker of increased cardiovascular risk: A meta - analysis. Vasc Health Risk Manag. 2009;5:185-97. doi: 10.2147/vhrm.s4822
- Bastos Gonçalves F, Voûte M.T, Hoeks S.E, Chonchol M.B, Boersma E.E, Stolker R.J, Verhagen H.J. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta - analysis. Heart. 2012;98(13):988-94. doi: 10.1136/heartjnl-2011-301464
- Асланян Н.С., Бланкова З.Н., Виценя М.В., Михайлов Г.В., Кулев Б.Д., Агеев Ф.Т. Взаимосвязь артериального кальциноза и остеопороза. Влияние терапии бисфосфонатами на сосудистую стенку. Сердце: журнал для практикующих врачей. 2016;3(15):151-60. doi: 10.18087/rhj.2016.3.2215
- Christian R.C, Harrington S, Edwards W.D, Oberg A.L, Fitzpatrick L.A. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002;87(3):1062-7. doi: 10.1210/jcem.87.3.8354
- Hjortnaes J, Butcher J, Figueiredo J.L, Riccio M, Kohler R.H, Kozloff K.M, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31(16):1975-84. doi: 10.1093/eurheartj/ehq237
- Tintut Y, Demer L.L. Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab. 2014;25(2):53-9. doi: 10.1016/j.tem.2013.10.001
- Ярославцева М.В., Ульянова И.Н., Галстян Г.Р., Ильин А.В., Никанкина Л.В., Ремизов О.В., Дедов И.И. Система остеопротегерин (opg) лиганд рецептора - активатора ядерного фактора каппа-В (RANKL) у пациентов с сахарным диабетом, медиакальцинозом и облитерирующим атеросклерозом артерий нижних конечностей. Сахарный диабет. 2009;(1):25-32. doi: 10.14341/2072-0351-5416
- Cauley J.A. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243-51. doi: 10.1093/gerona/glt093
- Burge R, Dawson-Hughes B, Solomon D.H, Wong J.B, King A, Tosteson A. Incidence and economic burden of osteoporosis - related fractures in the United States, 2005-2025. J Bone Miner Res. 2006;22(3):465-75. doi: 10.1359/jbmr.061113
- Magaziner J, Fredman L, Hawkes W, Hebel J.R, Zimmerman S, Orwig D.L, Wehren L. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community - dwelling aged. Am J Epidemiol. 2003;157(11):1023-31. doi: 10.1093/aje/kwg081
- Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633-50. doi: 10.1007/s00198-009-0920-3
- Haentjens P, Magaziner J, Colón-Emeric C.S, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta - analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380-90. doi: 10.7326/0003-4819-152-6-201003160-00008
- Cauley J.A, Danielson M.E, Boudreau R.M, Forrest K.Y, Zmuda J.M, Pahor M, Tylavsky F.A, Cummings S.R, Harris T.B, Newman A.B. Health ABC Study. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007;22(7):1088-95. doi: 10.1359/jbmr.070409
- Barbour K.E, Boudreau R, Danielson M.E, Youk A.O, Wactawski-Wende J, Greep N.C, La Croix A.Z, Jackson R.D, Wallace R.B, Bauer D.C, Allison M.A, Cauley J.A. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res. 2012;27(5):1167-76. doi: 10.1002/jbmr.1559
- Ing S.W, Orchard T.S, Lu B, La Monte M.J, Barbour K.E, Cauley J.A, Jackson R.D. TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association. J Clin Endocrinol Metab. 2015100(9):3380-7. doi: 10.1210/JC.2015-1662
- Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high - density lipoprotein cholesterol and decreases low - density lipoprotein cholesterol. J Bone Miner Res. 2010;15(3):599-604. doi: 10.1359/jbmr.2000.15.3.599
- Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in Carotid Intima-Media Thickness after 1-Year Therapy with Etidronate for Osteopenia Associated with Type 2 Diabetes. J Clin Endocrinol Metab. 2000:85(8):2793-6. doi: 10.1210/jcem.85.8.6748
- Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long - term hemodialysis. Am J Kidney Dis. 2004;44(4):680-8. doi: 10.1053/j.ajkd.2004.06.009
- Kawahara T, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327-35. doi: 10.1161/CIRCULATIONAHA.113.001534
- Kranenburg G, Bartstra J.W, Weijmans M, de Jong P.A, Mali W.P, Verhaar H.J, Visseren F.L.J, Spiering W. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta - analysis. Atherosclerosis. 2016;252:106-15. doi: 10.1016/j.atherosclerosis.2016.06.039
- Kang J.H, Keller J.J, Lin H.C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow - up study. Osteoporos Int. 2013;24(1):271-7. doi: 10.1007/s00198-012-2213-5
- Lu P.Y, Hsieh C.F, Tsai Y.W, Huang W.F. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther. 2011;33(9):1173-9. doi: 10.1016/j.clinthera.2011.07.012
- Wolfe F, Bolster M.B, O'Connor C.M, Michaud K, Lyles K.W, Colón-Emeric C.S. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28(5):984-91. doi: 10.1002/jbmr.1792
- Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima - media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16(4):689-93. doi: 10.1097/gme.0b013e318194cafd
- Santos L.L, Cavalcanti T.B, Bandeira F.A. Vascular effects of bisphosphonates - a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47-54. doi: 10.4137/CMED.S10007
- Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010;339(6):519-24. doi: 10.1097/MAJ.0b013e3181db6dfe
- D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski M.J, Vetrovec G.W, Frati G, Presutti D.G, Quadri G, Moretti C, Gaita F, Zoccai G.B. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta - regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178-85. doi: 10.1016/j.atherosclerosis.2012.10.065
- Mak A, Cheung M.W, Ho R.C, Cheak A.A, Lau C.S. Bisphosphonates and atrial fibrillation: Bayesian meta - analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord. 2009;10:113. doi: 10.1186/1471-2474-10-113
- Pazianas M, Compston J, Huang C.L. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2-10. doi: 10.1359/jbmr.091201
- Kim D.H, Rogers J.R, Fulchino L.A, Kim C.A, Solomon D.H, Kim S.C. Bisphosphonates and risk of cardiovascular events: a meta - analysis. PLoS One. 2015;10(4):e0122646. doi: 10.1371/journal.pone.0122646
![](/img/style/loading.gif)